论文部分内容阅读
目的观察肾康注射液治疗慢性肾脏病(CKD)的临床疗效。方法选取平煤神马医疗集团总医院肾内科2016年1-6月收治的早期慢性肾脏病患者112例为研究对象,以随机数字表法分组,分为观察组和对照组,每组56例。对照组使用常规疗法进行治疗,观察组在此基础上,给予肾康注射液治疗。一个疗程后,对比两组患者治疗前后24 h尿蛋白、尿素氮(BUN)、血清肌酐(Scr)和内生肌酐清除率(Ccr)等各项肾功能指标。结果观察组的总有效率为98.2%高于对照组的91.1%,差异具有统计学意义(P<0.05);观察组的各项肾功能指标均高于对照组,差异具有统计学意义(P<0.05)。结论肾康注射液治疗CKD患者安全有效,不良反应小,患者易于接受使用。
Objective To observe the clinical effect of Shenkang injection on chronic kidney disease (CKD). Methods 112 cases of early chronic kidney disease admitted from Jan. to Jun. 2016 in Pingmu Shenma Medical Group General Hospital were enrolled and randomly divided into observation group and control group, with 56 cases in each group . The control group was treated with conventional therapy. On the basis of this observation group, Shenkang injection was given. After a course of treatment, urinary protein, urea nitrogen (BUN), serum creatinine (Scr) and endogenous creatinine clearance (Ccr) were compared between the two groups before and 24 hours after treatment. Results The total effective rate in the observation group was 98.2%, which was significantly higher than that in the control group (91.1%, P <0.05). The renal function indexes in the observation group were significantly higher than those in the control group (P <0.05). Conclusion Shenkang injection in patients with CKD safe and effective, adverse reactions, patients are easy to accept use.